Evaluation of the Efficacy of Zactran® Injectable Solution (150 mg gamithromycin/ml) in the Control of Bovine Respiratory disease in Germany in Comparison to Draxxin® Injectable Solution (100 mg Tulathromycin/ml)

A field trial was conducted to evaluate the efficacy of Zactran injectable solution ( 150 mg gamithromycin/ml) in the control of bovine respiratory disease in comparison to Draxxin injectable solution ( 100 mg tulathromycin/ml) on a German commercial calf rearing/fattening farm. One hundred and twenty newly arrived Brown Swiss male calves judged to be at high risk of developing bovine respiratory disease were split into two equal groups. The animals in each group were treated either with gamithromycin at 6 mg/kg or with tulathromycin at 2.5 mg/kg by subcutaneous injection. All animals were weighed individually on Days 1, 69, and 100. Weight gain was defined as the main criterion for comparison in this study. Animals treated with Zactran had numerically higher weight gains throughout the study, although differences between those treated with Zactran and Draxxin were not statistically significant.